The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
Open accessAbstract
Imatinib, a tyrosine kinase inhibitor (TKI) of BCR-ABL, was the standard first-line therapy for chronic myeloid leukemia (CML) for almost 10 years. Dasatinib and nilotinib, two newer drugs with higher potency than imatinib against BCR-ABL and activity against most imatinib-resistant BCR-ABL mutations, have each shown superior efficacy compared with imatinib for first-line treatment of chronic-phase CML in randomized phase 3 trials. With 14 months follow-up time, available data suggest no obvious differences in efficacy between dasatinib and nilotinib. Compared with imatinib, dasatinib is associated with higher rates of pleural effusion and thrombocytopenia, but lower rates of edema, gastrointestinal AEs, musculoskeletal AEs, and rash. Nilotinib is associated with higher rates of dermatologic toxicity, headache, and biochemical abnormalities associated with hepatic and pancreatic toxicity compared with imatinib, but lower rates of edema, gastrointestinal AEs, muscle spasm, and neutropenia. Several studies have shown that poor adherence to imatinib detrimentally affects responses and should be considered in patients with a suboptimal response. The different dosing requirements of dasatinib (once daily with or without food) and nilotinib (twice daily with fasting) may be an additional factor in selecting frontline agents. This review compares and contrasts the three FDA approved first line TKI agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osterberg, L., & Blaschke, T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050100 · Cited by 7,974
O'Hare, T., Walters, D. K., Stoffregen, E. P., Jia, T., Manley, P. W., Mestan, J., Cowan-Jacob, S. W., Lee, F. Y., Heinrich, M. C., Deininger, M. W. N., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0259 · Cited by 1,036
Bradeen, H. A., Eide, C. A., O'Hare, T., Johnson, K. J., Willis, S. G., Lee, F. Y., Druker, B. J., & Deininger, M. W. (2006) · Blood · doi:10.1182/blood-2006-02-004580 · Cited by 393
Darkow, T., Henk, H. J., Thomas, S. K., Feng, W., Baladi, J.-F., Goldberg, G. A., Hatfield, A., & Cortes, J. (2007) · PharmacoEconomics · doi:10.2165/00019053-200725060-00004 · Cited by 271
Masiello, D., Gorospe, G., & Yang, A. S. (2009) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-2-46 · Cited by 66
Cited by
Matching-Adjusted Indirect Comparisons: A New Tool for Timely Comparative Effectiveness Research
Signorovitch, J. E., Sikirica, V., Erder, M. H., Xie, J., Lu, M., Hodgkins, P. S., Betts, K. A., & Wu, E. Q. (2012) · Value in Health · doi:10.1016/j.jval.2012.05.004 · Cited by 505
LncRNA MEG3 Regulates Imatinib Resistance in Chronic Myeloid Leukemia via Suppressing MicroRNA-21
Zhou, X., Yuan, P., Liu, Q., & Liu, Z. (2017) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2016.162 · Cited by 78
Adherence to oral tyrosine kinase inhibitor therapies in chronic myeloid leukemia
Gater, A., Heron, L., Abetz-Webb, L., Coombs, J., Simmons, J., Guilhot, F., & Rea, D. (2012) · Leukemia Research · doi:10.1016/j.leukres.2012.01.021 · Cited by 59
Hyaluronan abrogates imatinib-induced senescence in chronic myeloid leukemia cell lines
Lompardía, S., Díaz, M., Pibuel, M., Papademetrio, D., Poodts, D., Mihalez, C., Álvarez, É., & Hajos, S. (2019) · Scientific Reports · doi:10.1038/s41598-019-47248-8 · Cited by 19
Dominy, K. M., Claudiani, S., O’Hare, M., Szydlo, R., Gerrard, G., Foskett, P., Foroni, L., Milojkovic, D., Apperley, J. F., & Khorashad, J. (2022) · British Journal of Haematology · doi:10.1111/bjh.18026 · Cited by 11
Metadata
- Authors
- Wei, G., Rafiyath, S., & Liu, D.
- Venue
- Journal of Hematology & Oncology
- Published
- 2010-11-26
- Volume
- 3
- Issue
- 1
- Pages
- 47-47
- ISSN
- 1756-8722 (ISSN-L)
- OpenAlex
- W2153151008
- Cited by
- 170
- References
- 5
- FWCI
- 10.60
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib. https://app.cochat.ai/papers/10.1186/1756-8722-3-47
- The paper
- Wei, G., Rafiyath, S., & Liu, D. (2010). First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib. Journal of Hematology & Oncology. https://doi.org/10.1186/1756-8722-3-47
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.